The drug Aklast, analogues of the drug (Veroclast, Blaster, Zolendronat-Teva and others) can slow down the destruction of bone tissue. Zelendron acid - the active component - is part of the class of bisphosphonates (synthetic substances that prevent bone loss).
The drug "Aklast". Description
The drug is available in the form of a solution for infusion.
After intravenous administration, the active component is distributed into the bone tissue quickly. Like other bisphosphonates, Zelendron acid is localized mainly in the areas of resorption (destruction).
Preventing destruction, the active component does not adversely affect the mechanical properties, bone formation and mineralization process.
The drug "Aklast". Instructions: indications
The medication is prescribed for Paget's bone disease (deforming osteitis), postmenopausal osteoporosis (to reduce the likelihood of fractures in the spine, femur and other bones and increase their mineral density), to prevent fractures after bone injuries in the hip joint.
Means of Aklast. Instruction: dosage regimen
Before the introduction of the drug, it is necessary to ensure optimal hydration (water saturation) of the body. This is especially important when using diuretic therapy.
For the prevention of fractures after injuries of the hip joint and the treatment of osteoporosis of postmenopausal osteoporosis, the Aklast drug recommends administering five milligrams (once) by intravenous infusion once a year. Against the background of therapy, calcium and vitamin D preparations should be taken simultaneously.
In the treatment of Paget's disease, the intravenous administration of the Aklast medication, the instruction recommends a dose of five milligrams in one hundred milliliters of an aqueous solution, also administered intravenously using a separate infusion system. The introduction time is not less than fifteen minutes, the speed should be constant. Due to the fact that Paget's disease is characterized by progressive bone destruction, all patients with this pathology are recommended to take an additional daily intake of vitamin D and calcium during the first ten days after the infusion.
The first administration of the Aklast drug causes a prolonged period of remission of deforming osteitis. To date, there is no specific information on the re-treatment of Paget's disease. However, such treatment is possible if the patient has a relapse. The secondary development of the pathology is characterized by the following symptoms: the absence of normalization of serum alkaline phosphatase , an increase in the dynamics of its level, as well as the presence of clinical symptoms of Paget's disease, identified after twelve months after the use of the dose of the drug Aklast.
The drug is not recommended for patients with severe renal impairment.
Elderly and patients with impaired liver function, dosage adjustment is not required.
Due to the lack of data on the safety and effectiveness of the use of the drug "Aklast" in patients under eighteen years of age, they are not prescribed a drug.
After the introduction of the medication, it is likely that a fever, flu-like syndrome develops, fatigue increases, swelling (rarely), malaise, asthenia, and chills occur. Frequent negative reactions are headaches, lethargy, dizziness, shortness of breath. Sometimes paresthesia, fainting, tremors, drowsiness may occur. Patients may feel pain in the spine and bones. Perhaps the development of myalgia, arthralgia, dyspepsia, vomiting, nausea and other side effects.
The drug is contraindicated in case of lactation, hypocalcemia, pregnancy, hypersensitivity.